FDA Approval Age for Tacrolimus Ointment
Tacrolimus ointment is FDA-approved for patients 2 years of age and older. Specifically, the 0.03% formulation is approved for children aged 2-15 years, while the 0.1% formulation is approved for patients 16 years and older 1.
FDA-Approved Age Stratification
The FDA approval structure for tacrolimus ointment is age-specific:
- Ages 2-15 years: 0.03% tacrolimus ointment only
- Ages 16 years and older: 0.1% tacrolimus ointment (0.03% also remains an option)
- Under 2 years: Not FDA-approved
This approval applies to short-term or intermittent long-term treatment of atopic dermatitis in patients who are unresponsive to or intolerant of other conventional therapies, or in whom these therapies are inadvisable because of potential risks 2.
Off-Label Use in Children Under 2 Years
While not FDA-approved, tacrolimus is used off-label in children under 2 years when necessary. The American College of Allergy, Asthma and Immunology guidelines acknowledge that "in children less than 2 years of age with poorly controlled persistent AD who require more than hydration and use of emollients to keep their skin disease under control, use of off-label therapy might be necessary because most topical steroids or other immunomodulators have not been studied or approved in this age group" 2.
Clinical evidence supports off-label use with appropriate monitoring. A retrospective study of 12 patients younger than 2 years treated with tacrolimus ointment showed improvement in symptoms with no significant adverse effects and blood levels consistently below 1.5 ng/mL 3. A more recent 36-month prospective study in 152 children aged 1-3 years demonstrated comparable safety and efficacy profiles between tacrolimus (0.03% and 0.1%) and topical corticosteroids, with no malignancies or severe infections 4.
Important Caveats for Off-Label Use
When using tacrolimus off-label in children under 2 years:
- Monitor for systemic absorption, though studies show minimal blood levels (typically <1.5 ng/mL) 3
- Avoid use in immunocompromised patients
- Do not use with concurrent phototherapy
- Avoid in patients with severely impaired skin barrier function (e.g., Netherton syndrome) that might result in immunosuppressive blood levels 2
- The long-term effect on the developing immune system in infants is not known 2
Black Box Warning Context
Both tacrolimus and pimecrolimus carry a black box warning regarding theoretical malignancy risk, though current evidence does not support increased lymphoma rates. Post-marketing surveillance data shows lymphoma incidence in topical pimecrolimus-exposed populations is up to approximately 54-fold less than in the general US population 5. The task force concluded that "current data do not support the use of the black box warning" based on lack of evidence linking topical use to malignancy 2.